Health Catalyst (HCAT) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Wall Street analysts expect Health Catalyst (HCAT) to post quarterly earnings of $0.05 per share in its upcoming report, which indicates a year-over-year decline of 28.6%. Revenues are expected to be $75.08 million, down 1.7% from the year-ago quarter.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.That said, let's delve into the average estimates of some Health Catalyst metrics that Wall Street analysts commonly model and monitor.Analysts' assessment points toward 'Revenue- Professional services' reaching $23.08 million. The estimate indicates a change of -16.7% from the prior-year quarter.According to the collective judgment of analysts, 'Revenue- Technology' should come in at $52.00 million. The estimate indicates a year-over-year change of +6.9%.The average prediction of analysts places 'Adjusted Gross Profit- Professional Services' at $4.45 million. Compared to the current estimate, the company reported $4.72 million in the same quarter of the previous year.The consensus estimate for 'Adjusted Gross Profit- Technology' stands at $34.90 million. Compared to the current estimate, the company reported $31.57 million in the same quarter of the previous year. View all Key Company Metrics for Health Catalyst here>>> Health Catalyst shares have witnessed a change of +7% in the past month, in contrast to the Zacks S&P 500 composite's +1.3% move. With a Zacks Rank #3 (Hold), HCAT is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Health Catalyst, Inc. (HCAT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks